Novo Nordisk

from Wikipedia, the free encyclopedia
Novo Nordisk A / S

logo
legal form Aktieselskab
Aktiengesellschaft (Denmark)
ISIN DK0060534915
founding 1923
Seat Bagsværd , DenmarkDenmarkDenmark 
management Sten Scheibye
(Chairman of the board),
Lars Fruergaard Jørgensen (President and CEO),
Jesper Brandgaard (CFO)
Number of employees 43,258 (2019)
sales 122.0 billion DKK (18 billion euros ) (2019)
Branch pharmacy
Website www.novonordisk.com

Novo Nordisk A / S manufactures and markets pharmaceutical products and services. Since it was founded in Denmark in 1923, the company has grown to become a global leader in the diabetes sector . The company is also represented in the areas of blood coagulation drugs , growth hormone therapy and hormone replacement therapy .

Novo Nordisk is divided into an umbrella company, Novo Holdings , which also includes Novozymes A / S and NNIT . The company's main factory is in Bagsværd in the greater Copenhagen area . In addition to the headquarters in Denmark, Novo Nordisk has production sites in six other countries, as well as representatives or offices in 79 countries. The German headquarters have been in Mainz since August 1958 . In the German branch in Mainz, 70% of all phase 1 studies in the field of diabetes are coordinated and documented.

Novo Nordisk has been awarding the Novo Nordisk Media Prize, endowed with 12,000 euros, for journalistic articles on diabetes since 2002.

Ownership structure

All A shares in Novo Nordisk A / S have been owned by Novo Holdings A / S since December 31, 1999, which in turn is owned by the Novo Nordisk Foundation; This in turn is a non-profit foundation, the aim of which is to provide a stable basis for the companies of the Novo Group, and to participate in scientific, humanitarian and social progress. The A shares represent 25.5% of the total share capital and 68.5% of the votes. This means that Novo Holdings A / S always has the majority of votes at the general meeting.

history

Novo Nordisk was created in 1989 through the merger of the two Danish companies Novo Industri A / S and Nordisk Gentofte A / S.

  • 1923 Nordisk Insulin Laboratory (later Nordisk Gentofte) is founded.
  • 1925 Novo Terapeutisk Laboratorium (later Novo Industri) is founded.
  • 1932 Nordisk Insulin Laboratory establishes the Steno Memorial Hospital.
  • 1938 Novo founds the Hvidøre Diabetes Sanatorium.
  • 1941 Novo launches its first enzyme, trypsin. It is extracted from the pancreas of animals and used in the tanning of leather.
  • 1946 Nordisk develops Isophane Insulin NPH Insulin , a neutral insulin with an extended duration of action.
  • 1958 Novo founds its German headquarters in Mainz. 1969 Construction of the Arne Jacobsen Building
  • 1974 Novos B shares are listed on the Copenhagen Stock Exchange.
  • 1981 Novo is the first Scandinavian company to be listed on the New York Stock Exchange.
  • 1982 Human Monocomponent Insulin is released - the world's first insulin preparation identical to human insulin. It is extracted from the pancreas of pigs and then processed into human insulin.
  • 1985 NovoPen - an injection system with exchangeable insulin cartridges comes onto the market. The device looks like a fountain pen.
  • In 1989, the merger of Novo Industri A / S and Nordisk Gentofte A / S creates the world market leader in insulin production.
  • 1992 The Steno Memorial Hospital and the Hvidøre Hospital merge to form the Steno Diabetes Center.
  • 1996 NovoSeven - for the treatment of hemophilia patients with inhibitors - is launched.
  • 2000 Novo Nordisk is split into three separate companies under the umbrella of the Novo Group ( Novo Holdings A / S ): Novo Nordisk A / S, Novozymes A / S and NNIT .
  • 2001 InDuo - the world's first combined blood glucose meter and insulin injection system is presented.
  • 2001 Novo Nordisk becomes majority owner of the Brazilian pharmaceutical company Biobrás.

Web links

Individual evidence

  1. ↑ Novo Nordisk Annual Report 2019. Novo Nordisk, February 4, 2020, accessed June 11, 2020 .
  2. ↑ Novo Nordisk's operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates (CER) in 2019 , PM Novo Nordisk, February 5, 2020, accessed March 3, 2020
  3. ↑ NOVO NORDISK balance sheet income statement, key figures, turnover, profit. In: finanzen.net. Retrieved February 28, 2020 .
  4. ↑ At a Glance Novo Nordisk, accessed February 2, 2019
  5. ↑ Markus Grill: PR Tricks 1: Pharmaceutical Financed Journalist Awards ( Memento from October 19, 2007 in the Internet Archive ) from August 29, 2007
  6. ↑ Novo Nordisk A / S: Novo Nordisk History ( Memento from March 13, 2015 in the Internet Archive )
  7. ↑ Novo Nordisk celebrates its 50th anniversary in Germany ( Memento from January 7, 2012 in the Internet Archive ) (PDF; 46 kB)